Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Glaxo Submits First Regulatory Application for Daprodustat
by Zacks Equity Research
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
The Zacks Analyst Blog Highlights: Microsoft, Merck, Walmart, Coca-Cola and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Merck, Walmart, Coca-Cola and Visa
Buy 5 Dow Stocks That Have Surged Despite Market Gyrations
by Nalak Das
Some members of the Dow 30 Index have offered impressive returns in the past three months and still have upside left.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
by Zacks Equity Research
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
Moleculin Completes Enrollment in Early-Stage Cancer Study
by Zacks Equity Research
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
by Zacks Equity Research
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
by Zacks Equity Research
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
Top Stock Reports: Mastercard, Verizon, Coca-Cola & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Mastercard (MA), Verizon (VZ) and Coca-Cola (KO).
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRK) Outperforming Other Medical Stocks This Year?
Stock Market News For Jul 31, 2019
by Zacks Equity Research
Stocks closed in the red on Tuesday after Trump???s renewed attacks on China diminished investor???s hopes of a positive outcome from trade talks.
Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge